Physician profile
Kyle D Rose
NPI 1073811352
$4,908.85
in general payments reported to CMS, 2019-2025
31 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $228 · 2021: $500 · 2022: $799 · 2023: $681 · 2024: $1,017 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756 · Education: $26.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.22 |
| Education | $26.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.04 | 2019-2025 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $700.06 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $544.73 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.74 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $327.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $245.91 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $243.47 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $226.60 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $187.52 | 2022-2025 | Dupixent |
| Amgen INC. | $157.50 | 2021-2025 | Avsola, Amjevita, Uplizna |
| Gilead Sciences, INC. | $127.55 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $118.03 | 2022-2024 | Linzess |
| Celgene Corporation | $114.26 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $76.08 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $69.25 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.27 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $43.91 | 2019-2021 | |
| Pfizer INC. | $43.73 | 2019-2025 | |
| Organon LLC | $38.03 | 2022-2024 | Hadlima |
| Celltrion USA INC. | $34.47 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $27.30 | 2025 | Iqirvo |
| Covidien LP | $23.42 | 2019 | |
| Ardelyx, INC. | $21.38 | 2023 | Ibsrela |
| Olympus America INC. | $19.46 | 2022 | |
| Lilly USA, LLC | $17.15 | 2025 | Omvoh |
| Alfasigma USA, INC. | $16.98 | 2020 | |
| Welch Allyn | $16.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.93 | 2025 | Givlaari |
| Baxter Healthcare | $12.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Phathom Pharmaceuticals, INC. | $5.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.